Enhanced histone deacetylase enzyme activity in primary myelofibrosis.
about
Clinical use and applications of histone deacetylase inhibitors in multiple myelomaTherapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromesEvolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative NeoplasmsTargeting JAK2 in the therapy of myeloproliferative neoplasmsNovel therapies for myelofibrosisInhibition of histone deacetylase 6 restores innate immune cells in the bone marrow in a lethal septic modelA DDX5 S480A polymorphism is associated with increased transcription of fibrogenic genes in hepatic stellate cellsHDAC8 overexpression in mesenchymal stromal cells from JAK2+ myeloproliferative neoplasms: a new therapeutic target?Blocking sirtuin 1 and 2 inhibits renal interstitial fibroblast activation and attenuates renal interstitial fibrosis in obstructive nephropathy.Histone deacetylase: a potential therapeutic target for fibrotic disordersA novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2.Efficacy of vorinostat in a murine model of polycythemia veraDysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma.JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasmsAdvances in myelofibrosis: a clinical case approach.Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives.Deactylase inhibition in myeloproliferative neoplasms.JAK2 inhibitors in the treatment of myeloproliferative neoplasms.Emerging drugs for the treatment of myelofibrosis.Primary myelofibrosis and its targeted therapy.Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms.Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms.Histone deacetylase in chronic lymphocytic leukemia.
P2860
Q26745930-EA5556C4-A87A-4D60-A21B-94AF5FBBE6E7Q26752940-4C4F13D4-02D9-4E08-B160-9039922192BEQ26766319-F57817FB-14BC-4182-A815-E0EA25177459Q26860796-2B7B50A5-22EC-4B04-8A2F-0FF19B10C5E1Q28081693-95A9F1EA-5E31-4773-A683-6A76C1228787Q30144009-03536C1F-ED31-41AE-B288-1BA22AD55956Q33648379-9A5E9D7D-75C3-467B-8A8D-5E5ECDB34E04Q33709629-20512D23-3460-405B-9B5C-36A1282DFDA7Q33943997-D05F4E71-8A7E-425A-B3AF-B10146ED53BBQ34257607-C2348E85-B4F1-4408-8595-4168D9E4071AQ35679582-D6E2C681-6938-4567-A636-97D70B6877F8Q35909673-846F5066-854C-489D-A6AE-D637C2A41E12Q36214527-04D7375C-8D9F-4810-A6BA-B9287616F3B7Q37168138-F783AEEC-00F4-468A-90F2-F6429C08F1C5Q37212674-27B3D8C9-A7C3-426E-A9B3-37982C5D8697Q37310619-44C34652-0CE0-4D4F-9ADC-776D1847E06CQ37815421-7E44BB70-CBB8-4D0D-8EAE-F4EF02F1C1E4Q38044736-2479FFC1-17D1-44DC-8551-48EC1576CE97Q38543775-CCB0820D-0ACB-43E6-BBCE-F081A27B6607Q38931426-DCC3267B-4040-4042-BB7C-3781E60B832CQ38984578-AC4DBE22-B8D4-46AA-B484-AACF3FF8BAF1Q39722432-15EC4A88-6E64-49B3-9BD8-1D1805F1A1B2Q53192790-BDC1DE04-BFE5-4726-A867-6E7A28C77886
P2860
Enhanced histone deacetylase enzyme activity in primary myelofibrosis.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Enhanced histone deacetylase enzyme activity in primary myelofibrosis.
@en
Enhanced histone deacetylase enzyme activity in primary myelofibrosis.
@nl
type
label
Enhanced histone deacetylase enzyme activity in primary myelofibrosis.
@en
Enhanced histone deacetylase enzyme activity in primary myelofibrosis.
@nl
prefLabel
Enhanced histone deacetylase enzyme activity in primary myelofibrosis.
@en
Enhanced histone deacetylase enzyme activity in primary myelofibrosis.
@nl
P2093
P2860
P1433
P1476
Enhanced histone deacetylase enzyme activity in primary myelofibrosis.
@en
P2093
Inna Sominsky
Jack Burton
Jen Chin Wang
Seema Naik
Theresa Dumlao
Thong Chang
Ying-Yi Xiao
P2860
P304
P356
10.1080/10428190802527699
P577
2008-12-01T00:00:00Z